GSK plc (GSK)
A+
Pipeline Grade
Drug Pipeline (70 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
TEBIPENEM PIVOXIL HYDROBROMIDE
UTEBZI |
APPROVED | — |
|
DOSTARLIMAB-GXLY
JEMPERLI |
APPROVED | — |
|
FLUTICASONE FUROATE
ARNUITY ELLIPTA |
APPROVED | — |
|
ATOVAQUONE, PROGUANIL HYDROCHLORIDE
MALARONE |
APPROVED | — |
|
SALMETEROL XINAFOATE
SEREVENT |
APPROVED | — |
|
GEPOTIDACIN MESYLATE
BLUJEPA |
APPROVED | — |
|
ZANAMIVIR
RELENZA |
APPROVED | — |
|
NIRAPARIB TOSYLATE
ZEJULA |
APPROVED | — |
|
UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE
ANORO ELLIPTA |
APPROVED | — |
|
MEPOLIZUMAB
NUCALA |
APPROVED | — |
|
TAFENOQUINE SUCCINATE
KRINTAFEL |
APPROVED | — |
|
LINERIXIBAT
LYNAVOY |
APPROVED | — |
|
MOMELOTINIB DIHYDROCHLORIDE
OJJAARA |
APPROVED | — |
|
IBREXAFUNGERP CITRATE
BREXAFEMME |
APPROVED | — |
|
VALACYCLOVIR HYDROCHLORIDE
VALTREX |
APPROVED | — |
|
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE
TRELEGY ELLIPTA |
APPROVED | — |
|
CIMETIDINE
TAGAMET |
APPROVED | — |
|
MUPIROCIN CALCIUM
BACTROBAN |
APPROVED | — |
|
SUMATRIPTAN SUCCINATE
IMITREX |
APPROVED | — |
|
PROCHLORPERAZINE
COMPAZINE |
NDA | — |
|
MUPIROCIN
BACTROBAN |
NDA | — |
|
CIMETIDINE HYDROCHLORIDE
TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER |
NDA | — |
|
TRIFLUOPERAZINE HYDROCHLORIDE
STELAZINE |
NDA | — |
|
BACITRACIN ZINC, POLYMYXIN B SULFATE
POLYSPORIN |
NDA | — |
|
CEFUROXIME AXETIL
CEFTIN |
NDA | — |
|
DIPHENYLPYRALINE HYDROCHLORIDE
HISPRIL |
NDA | — |
|
SUMATRIPTAN
IMITREX |
NDA | — |
|
DIPHENIDOL HYDROCHLORIDE
VONTROL |
NDA | — |
|
HYDROCHLOROTHIAZIDE, LABETALOL HYDROCHLORIDE
TRANDATE HCT |
NDA | — |
|
PIPERAZINE CITRATE
ANTEPAR |
NDA | — |
|
OXACILLIN SODIUM
BACTOCILL |
NDA | — |
|
CHLORPHENIRAMINE MALEATE
TELDRIN |
NDA | — |
|
PERMETHRIN
NIX |
NDA | — |
|
CARBENICILLIN DISODIUM
PYOPEN |
NDA | — |
|
PSEUDOEPHEDRINE HYDROCHLORIDE
SUDAFED 12 HOUR |
NDA | — |
|
BECLOMETHASONE DIPROPIONATE
BECLOVENT |
NDA | — |
|
DECAMETHONIUM BROMIDE
SYNCURINE |
NDA | — |
|
PROPYLIODONE
DIONOSIL OILY |
NDA | — |
|
NEOMYCIN SULFATE, POLYMYXIN B SULFATE
NEOSPORIN |
NDA | — |
|
CYCLIZINE LACTATE
MAREZINE |
NDA | — |
|
CHLORPROMAZINE
THORAZINE |
NDA | — |
|
ISOPROPAMIDE IODIDE
DARBID |
NDA | — |
|
ACETAMINOPHEN, CODEINE PHOSPHATE
EMPRACET W/ CODEINE PHOSPHATE #4 |
NDA | — |
|
ONDANSETRON HYDROCHLORIDE
ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER |
NDA | — |
|
PSEUDOEPHEDRINE HYDROCHLORIDE, TRIPROLIDINE HYDROCHLORIDE
ACTIFED |
NDA | — |
|
LORATADINE
LORATADINE |
NDA | — |
|
RANITIDINE HYDROCHLORIDE
ZANTAC 150 |
NDA | — |
|
AMPICILLIN SODIUM
TOTACILLIN-N |
NDA | — |
|
CEFTAZIDIME
PENTACEF |
NDA | — |
|
LEUCOVORIN CALCIUM
WELLCOVORIN |
NDA | — |
|
NAFCILLIN SODIUM
NALLPEN |
NDA | — |
|
HALOFANTRINE HYDROCHLORIDE
HALFAN |
NDA | — |
|
BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BECONASE AQ |
NDA | — |
|
EZOGABINE
POTIGA |
NDA | — |
|
TRIPROLIDINE HYDROCHLORIDE
ACTIDIL |
NDA | — |
|
TICARCILLIN DISODIUM
TICAR |
NDA | — |
|
CLAVULANATE POTASSIUM, TICARCILLIN DISODIUM
TIMENTIN |
NDA | — |
|
METHOXAMINE HYDROCHLORIDE
VASOXYL |
NDA | — |
|
LAMIVUDINE
EPIVIR-HBV |
NDA | — |
|
AMPRENAVIR
AGENERASE |
NDA | — |
|
CETYL ALCOHOL, COLFOSCERIL PALMITATE, TYLOXAPOL
EXOSURF NEONATAL |
NDA | — |
|
DICLOXACILLIN SODIUM
DYCILL |
NDA | — |
|
RANITIDINE BISMUTH CITRATE
TRITEC |
NDA | — |
|
IDOXURIDINE
STOXIL |
NDA | — |
|
ALBUTEROL
VENTOLIN |
NDA | — |
|
CODEINE PHOSPHATE, PSEUDOEPHEDRINE HYDROCHLORIDE, TRIPROLIDINE HYDROCHLORIDE
ACTIFED W/ CODEINE |
NDA | — |
|
AMPICILLIN/AMPICILLIN TRIHYDRATE
TOTACILLIN |
NDA | Acne, Acne Vulgaris, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL), Alopecia, Alzheimer Disease, Alzheimer's Disease, Atopic Dermatitis, Bioequivalence of Amoxicillin, Cancer, Carcinoma, Hepatocellular, Cervical Cancer, Chronic Pruritus, Chronic Refractory Cough, Colitis, Ulcerative, Cough, Dermatitis Atopic, Dermatitis, Chronic, Dermatitis, Seborrheic, Diabetes Mellitus, Type 2, Diaper Rash, Digestive System Disease, Eczema, EGFR Mutated EGFR TKI Naive Metastatic NSCLC, Essential Thrombocythemia, Familial Mediterranean Syndrome, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Healthy, Healthy Volunteer, Hepatocellular Carcinoma, Ichthyosis, Lamellar, Kidney Diseases, Lupus Erythematosus, Discoid, Lupus Nephritis, Lymphoma, Diffuse Large B-Cell, Lymphoma, Non-Hodgkin's, Metabolic Syndrome X, Metastatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Multiple Myeloma, Neoplasms, Colorectal, Nephrotic Syndrome, Ne |
|
POLYMYXIN B SULFATE
AEROSPORIN |
NDA | — |
|
CEFONICID SODIUM
MONOCID |
NDA | — |
|
DAPRODUSTAT
JESDUVROQ |
NDA | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2026-09-10 | Phase3 Readout | — |
| 2026-09-29 | Phase3 Readout | — |
| 2026-09-30 | Phase3 Readout | — |
| 2026-10-14 | Phase3 Readout | — |
| 2026-10-31 | Phase2 Readout | — |
| 2026-11-30 | Phase1 Readout | — |
| 2026-12-03 | Phase1 Readout | — |
| 2026-12-09 | Phase1 Readout | — |
| 2026-12-11 | Phase3 Readout | — |
| 2027-01-15 | Phase3 Readout | — |
| 2027-02-24 | Phase2 Readout | — |
| 2027-03-01 | Phase2 Readout | — |
| 2027-03-05 | Phase2 Readout | — |
| 2027-03-10 | Phase2 Readout | — |
| 2027-03-19 | Phase2 Readout | — |
| 2027-04-22 | Phase2 Readout | — |
| 2027-04-23 | Phase2 Readout | — |
| 2027-05-01 | Phase3 Readout | — |
| 2027-05-31 | Phase2 Readout | — |
Active Clinical Trials (50)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07485283 | Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia | PHASE4 | Recruiting | 162,000 |
| NCT06638177 | Obesity and Obesity-Related Factors and Risk of Herpes Zoster (Shingles) and Postherpetic Neuralgia | OTHER | Active Not Recruiting | 200,000 |
| NCT07502560 | A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population A... | PHASE4 | Recruiting | 33,609 |
| NCT06206083 | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis | OTHER | Recruiting | 64 |
| NCT03543839 | Trial of Belimumab in Early Lupus | PHASE4 | Recruiting | 30 |
| NCT05879419 | Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases | PHASE4 | Active Not Recruiting | 2,005 |
| NCT05008081 | The CATALINA Study | OTHER | Recruiting | 1,000 |
| NCT05001087 | A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) | OTHER | Recruiting | 1,900 |
| NCT04140097 | Predictors of Acute Exacerbation in Patients With COPD - an Observational Study | OTHER | Active Not Recruiting | 355 |
| NCT05913700 | Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study) | OTHER | Active Not Recruiting | 3,067 |
| NCT06041386 | REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEcti... | PHASE4 | Active Not Recruiting | 336 |
| NCT06298448 | eGPA and Local Inflammation Within the Ear, Nose and Throat Area | OTHER | Recruiting | 150 |
| NCT05626777 | Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices | PHASE4 | Active Not Recruiting | 20 |
| NCT04578171 | Residual Exacerbations With Mepolizumab | OTHER | Recruiting | 60 |
| NCT06763783 | Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases | PHASE4 | Enrolling By Invitation | 240 |
| NCT07099898 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) | PHASE3 | Recruiting | 420 |
| NCT06979323 | Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | PHASE3 | Recruiting | 150 |
| NCT05201547 | Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line | PHASE3 | Active Not Recruiting | 260 |
| NCT06959095 | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T... | PHASE3 | Recruiting | 981 |
| NCT06388733 | A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma | PHASE3 | Active Not Recruiting | 450 |
| NCT06855160 | A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rub... | PHASE3 | Recruiting | 911 |
| NCT04167358 | Linerixibat Long-term Safety, and Tolerability Study | PHASE3 | Active Not Recruiting | 242 |
| NCT06961214 | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T... | PHASE3 | Recruiting | 960 |
| NCT06666491 | An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken... | PHASE3 | Recruiting | 300 |
| NCT05690841 | FocaL Mass Drug Administration for Vivax Malaria Elimination | PHASE3 | Recruiting | 7,530 |
| NCT06572384 | A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tiss... | PHASE3 | Recruiting | 440 |
| NCT07221227 | A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | PHASE3 | Recruiting | 1,200 |
| NCT06679101 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab... | PHASE3 | Recruiting | 520 |
| NCT07177339 | eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO... | PHASE3 | Recruiting | 1,196 |
| NCT05263934 | Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulo... | PHASE3 | Active Not Recruiting | 163 |
| NCT05757102 | A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | PHASE3 | Recruiting | 292 |
| NCT04651777 | Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma | PHASE3 | Active Not Recruiting | 31 |
| NCT05334368 | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | PHASE3 | Recruiting | 123 |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus D... | PHASE3 | Active Not Recruiting | 24 |
| NCT06757244 | DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer | PHASE2 | Recruiting | 35 |
| NCT05169554 | Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy | PHASE2 | Recruiting | 140 |
| NCT05583344 | Phase 2b Study of GSK4532990 in Adults With NASH | PHASE2 | Active Not Recruiting | 284 |
| NCT06077877 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK452410... | PHASE2 | Active Not Recruiting | 42 |
| NCT07150104 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and De... | PHASE2 | Active Not Recruiting | 14 |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | PHASE2 | Active Not Recruiting | 153 |
| NCT06747845 | Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progre... | PHASE2 | Recruiting | 68 |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | PHASE2 | Recruiting | 40 |
| NCT06517875 | Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | PHASE2 | Recruiting | 68 |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) | PHASE2 | Recruiting | 10 |
| NCT06114628 | Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB | PHASE2 | Recruiting | 2,500 |
| NCT04954859 | Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Su... | PHASE2 | Recruiting | 450 |
| NCT06381453 | Belimumab in Autoimmune Hepatitis | PHASE2 | Recruiting | 48 |
| NCT00999804 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | PHASE2 | Active Not Recruiting | 128 |
| NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | PHASE2 | Active Not Recruiting | 45 |
| NCT05087056 | Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents | PHASE2 | Active Not Recruiting | 312 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.